EW
Edwards Lifesciences insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$87.23
+13.9% over 12 months
Share price and insider trades
EW closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$27.7M
Insiders buying0
Insiders selling9
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Edwards Lifesciences insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $27.7M. 31 of 53 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 102 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 11SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 619 | $87.51 | $54K | -0.3% | — |
| Aug 31SEC | Andrew M. DahlSvp, Corporate Controller | Sell | 544 | $91.06 | $50K | -4.2% | — |
| Aug 28SEC | Annette BrulsCvp, Emeacla | Sell | 2,644 | $89.98 | $238K | -3.1% | — |
| Aug 26SEC | Daveen ChopraCvp, Tmtt, Surgical & Ihfm | Sell | 30,646 | $90.99 | $2.8M | -4.1% | — |
| Aug 26SEC | Wayne MarkowitzCvp, Japac | Sell | 1,240 | $91.47 | $113K | -4.6% | — |
| Aug 26SEC | Daveen ChopraCvp, Tmtt, Surgical & Ihfm | Sell | 1,154 | $91.76 | $106K | -4.9% | — |
| Aug 11SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 619 | $92.03 | $57K | -5.2% | — |
| Jul 30SEC | Wayne MarkowitzCvp, Japac | Sell | 146 | $86.03 | $13K | +1.4% | — |
| Jul 28SEC | Wayne MarkowitzCvp, Japac | Sell | 9,628 | $85.06 | $819K | +2.6% | — |
| Jul 27SEC | Bernard J ZovighianCEO | Sell | 2,921 | $83.93 | $245K | +3.9% | — |
| Jul 10SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 619 | $91.70 | $57K | -4.9% | — |
| Jun 30SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 619 | $91.40 | $57K | -4.6% | — |
| Jun 17SEC | Bernard J ZovighianCEO | Sell Plan | 523 | $87.92 | $46K | -0.8% | — |
| May 29SEC | Andrew M. DahlSvp, Corporate Controller | Sell | 568 | $86.08 | $49K | +1.3% | — |
| May 27SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell | 23,145 | $86.42 | $2.0M | +0.9% | — |
| May 22SEC | Daveen ChopraCvp, Tmtt & Surgical | Sell | 1,500 | $84.60 | $127K | +3.1% | — |
| May 18SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell | 9,968 | $82.07 | $818K | +6.3% | — |
| May 18SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell | 8,000 | $81.82 | $655K | +6.6% | — |
| May 18SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 620 | $81.14 | $50K | +7.5% | — |
| May 12SEC | Bernard J ZovighianCEO | Sell Plan | 35,506 | $77.92 | $2.8M | +11.9% | — |
| May 12SEC | Bernard J ZovighianCEO | Sell Plan | 845 | $78.40 | $66K | +11.3% | — |
| May 11SEC | Wayne MarkowitzCvp, Japac | Sell | 593 | $79.73 | $47K | +9.4% | — |
| May 4SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,019 | $83.98 | $86K | +3.9% | — |
| May 4SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,000 | $82.99 | $83K | +5.1% | — |
| May 4SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 19 | $83.99 | $2K | +3.9% | — |
| Apr 9SEC | Scott B. UllemCFO | Sell Plan | 8,324 | $79.79 | $664K | +9.3% | — |
| Apr 9SEC | Scott B. UllemCFO | Sell Plan | 4,676 | $80.50 | $376K | +8.4% | — |
| Apr 6SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,019 | $80.98 | $83K | +7.7% | — |
| Apr 2SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 18,004 | $80.05 | $1.4M | +9.0% | — |
| Apr 2SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 4,676 | $80.59 | $377K | +8.2% | — |
| Mar 11SEC | Scott B. UllemCFO | Sell Plan | 7,901 | $85.21 | $673K | +2.4% | — |
| Mar 11SEC | Scott B. UllemCFO | Sell Plan | 5,099 | $84.46 | $431K | +3.3% | — |
| Mar 11SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,019 | $85.38 | $87K | +2.2% | — |
| Mar 2SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 11,340 | $85.93 | $974K | +1.5% | — |
| Feb 26SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell | 24,000 | $83.84 | $2.0M | +4.0% | — |
| Feb 13SEC | Bernard J ZovighianCEO | Sell | 19,898 | $76.61 | $1.5M | +13.9% | — |
| Feb 13SEC | Bernard J ZovighianCEO | Sell | 2,532 | $77.13 | $195K | +13.1% | — |
| Jan 9SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,019 | $85.70 | $87K | +1.8% | — |
| Jan 6SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 8,708 | $85.98 | $749K | +1.5% | — |
| Jan 6SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 2,632 | $84.62 | $223K | +3.1% | — |
| Dec 12SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell | 5,900 | $83.74 | $494K | +4.2% | — |
| Dec 12SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell | 5,486 | $83.79 | $460K | +4.1% | — |
| Dec 12SEC | Heisz Leslie StoneDirector | Sell | 2,615 | $83.41 | $218K | +4.6% | — |
| Dec 12SEC | Daniel J. LippisCvp, Japac | Sell Plan | 1,019 | $84.03 | $86K | +3.8% | — |
| Dec 11SEC | Daveen ChopraCvp, Tmtt & Surgical | Sell | 2,000 | $84.38 | $169K | +3.4% | — |
| Dec 10SEC | Bernard J ZovighianCEO | Sell Plan | 21,487 | $85.21 | $1.8M | +2.4% | — |
| Dec 10SEC | Donald E Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 11,340 | $83.83 | $951K | +4.1% | — |
| Dec 10SEC | Bernard J ZovighianCEO | Sell Plan | 3,863 | $83.45 | $322K | +4.5% | — |
| Dec 9SEC | Scott B. UllemCFO | Sell Plan | 7,700 | $84.47 | $650K | +3.3% | — |
| Dec 8SEC | Wayne MarkowitzCvp, Japac | Sell | 583 | $86.01 | $50K | +1.4% | — |
| Nov 10SEC | Scott B. UllemCFO | Sell Plan | 10,026 | $83.02 | $832K | +5.1% | — |
| Nov 10SEC | Scott B. UllemCFO | Sell Plan | 2,974 | $83.30 | $248K | +4.7% | — |
| Nov 10SEC | Daniel J. LippisCvp, Japac | Sell Plan | 1,020 | $82.55 | $84K | +5.7% | — |
Insiders at Edwards Lifesciences
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Donald E Bobo Jr.Cvp,Strategy/Corp Development | — | $11.2M | May 27, 2026 | — |
| Bernard J ZovighianCEO | — | $7.0M | Jul 27, 2026 | — |
| Scott B. UllemCFO | — | $3.9M | May 11, 2026 | — |
| Daveen ChopraCvp, Tmtt, Surgical & Ihfm | — | $3.2M | Sep 11, 2026 | — |
| Wayne MarkowitzCvp, Japac | — | $1.0M | Sep 14, 2026 | — |
| Daniel J. LippisCvp, Tavr | — | $872K | Sep 11, 2026 | — |
| Annette BrulsCvp, Emeacla | — | $238K | Aug 28, 2026 | — |
| Heisz Leslie StoneDirector | — | $218K | May 8, 2026 | — |
| Andrew M. DahlSvp, Corporate Controller | — | $98K | Sep 14, 2026 | — |
| Theodora MistrasCFO | — | — | Jul 10, 2026 | — |
| Leslie C. DavisDirector | — | — | May 8, 2026 | — |
| David T FeinbergDirector | — | — | May 8, 2026 | — |
| Kieran GallahueDirector | — | — | May 8, 2026 | — |
| Paul A LavioletteDirector | — | — | May 8, 2026 | — |
| Steven R LorangerDirector | — | — | May 8, 2026 | — |
| Ramona SequeiraDirector | — | — | May 8, 2026 | — |
| Nicholas J ValerianiDirector | — | — | May 8, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about EW insiders
Are Edwards Lifesciences insiders buying EW stock?
In the past 12 months, 0 insiders reported open-market purchases of EW worth $0.
Are Edwards Lifesciences insiders selling EW stock?
9 insiders reported sales worth $27.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.